

Drug Monograph

Drug/Drug **INVOKAMET™ (canagliflozin and metformin**
 Class: **hydrochloride) tablets / Anti-hyperglycemic agent**
 Prepared for: MO HealthNet
 Prepared by: Xerox Heritage, LLC

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Invokamet™ is available as 50 mg/500 mg, 50 mg/1000 mg, 150 mg/500 mg, and 150 mg/1000 mg tablets containing 50-150 mg of canagliflozin and 500-1000 mg of metformin hydrochloride per tablet.

Manufacturer: Manufactured by: Janssen Ortho, LLC, Gurabo, PR 00778
 Manufactured for: Janssen Pharmaceuticals, Inc., Titusville, NJ 08560

Indications: Invokamet™ is a SGLT2 inhibitor and biguanide combination indicated to improve glycemic control concomitantly with diet and exercise in adult patients with Type II Diabetes Mellitus who are not controlled with canagliflozin or metformin alone or are already taking both drugs separately.

Costs: \$5.20 per tablet of Invokamet™ Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).

Status Recommendation: Prior Authorization (PA) Required Open Access
 Fiscal Edit PDL

Type of PA Criteria: Increased Risk of ADE Non-Preferred Agent
 Appropriate Indications No PA Required

Prepared By: Abbey Mahaney, Pharm. D. Candidate 2015
 Date: October 24, 2014